Abstract
Background and Aims One of the most important complications of heart transplantation is organ rejection, which is diagnosed on endomyocardial biopsies by pathologists. Computer-based systems could assist in the diagnostic process and potentially improve reproducibility. Here, we evaluated the feasibility of using deep learning in predicting the degree of cellular rejection from pathology slides as defined by the International Society for Heart and Lung Transplantation (ISHLT) grading system.
Methods We collected 1079 histopathology slides from 325 patients from three transplant centers in Germany. We trained an attention-based deep neural network to predict rejection in the primary cohort and evaluated its performance using cross validation and by deploying it to three cohorts.
Results For binary prediction (rejection yes/no) the mean Area Under the Receiver Operating Curve (AUROC) was 0.849 in the cross-validated experiment and 0.734, 0.729 and 0.716 in external validation cohorts. For a prediction of the ISHLT grade (0R, 1R, 2/3R), AUROCs were 0.835, 0.633 and 0.905 in the cross-validated experiment and 0.764, 0.597, 0.913, and 0.631, 0.633, 0.682, and 0.722, 0.601, 0.805 in the validation cohorts, respectively. The predictions of the AI model were interpretable by human experts and highlighted plausible morphological patterns.
Conclusions We conclude that artificial intelligence can detect patterns of cellular transplant rejection in routine pathology, even when trained on small cohorts.
Competing Interest Statement
JNK declares consulting services for Owkin, France and Panakeia, UK as well as reimbursement for scientific talks by MSD and Eisai. DW declares consulting services and honorary talks for Abiomed, AstraZeneca, Bayer, Berlin-Chemie, Novartis, Medtronic. CM declares honorary talks for AstraZeneca, Novartis, Heinen&Loewenstein, Boehringer Ingelheim-Lilly, Bayer, Pfizer, Sanofi, Aventis, Apontis, Abbott and meeting support from AstraZeneca, Novartis, Boehringer Ingelheim-Lilly. TL declares consulting fees from AstraZeneca, BMS, EISAI, Incyte, MSD, Roche, HepaRegeniX and honorary talks and travel support from Abbvie and Gilead. The other authors do not have anything to disclose.
Funding Statement
JNK and TL are supported by the German Federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and JNK is supported by the Max-Eder-Programme of the German Cancer Aid (grant 70113864). TL is supported by the European Research Council (ERC; Consolidator Grant No 771083). SS is funded by the German Research Foundation (DFG) through the research grant SO 1223/4-1. PB is supported by the German Research Foundation (DFG; Project-IDs 322900939, 454024652, 445703531), the European Research Council (ERC; Consolidator Grant No 101001791), the federal Ministry of Health (DEEP LIVER, ZMVI1-2520DAT111) and the Federal Ministry of Economic Affairs and Energy (EMPAIA, No. 01MK2002A). ML is supported by the German Foundation for the chronically ill (III. Grant). CM is funded by the German Center for Cardiovascular Research, Deutsche Stiftung fuer Herzforschung und Rolf M. Schwiete Stiftung. This research project is supported by the START-Program of the Faculty of Medicine of the RWTH Aachen University (148/21 to RDB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was carried out in accordance with the Declaration of Helsinki. This study is a retrospective analysis of digital images of anonymized archival tissue samples from three patient cohorts. Collection and anonymization of patients in all cohorts took place in each contributing centre. For the Regensburg cohorts, ethical approval was granted by the ethical Review board of the University Regensburg (ID: 21-2620-104). For the Hamburg and Aachen cohort, ethical approval of this retrospective investigation was not legally required due to local regulations (Berufsordnung fuer Aerzte). Nevertheless, the retrospective analysis of samples from Aachen and other collaborating centers was assessed by and approved by the Ethics commission of the Medical Faculty of RWTH Aachen University (EK315/19), confirming that no specific patient consent is required for this retrospective study of anonymized tissue samples.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.